Marinus Pharmaceuticals, Inc. provided revenue guidance for 2023. For the year, With the exceptional early performance of ZTALMY, the company increased revenue guidance for 2023 to a range of $17 million to $18.5 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.515 USD | -1.62% | +4.66% | -85.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-85.94% | 84.6M | |
+43.61% | 749B | |
+39.42% | 605B | |
-6.37% | 351B | |
+19.66% | 328B | |
+8.15% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+1.75% | 167B | |
+7.23% | 165B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for 2023